Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCDS0780A + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DCDS0780A + obinutuzumab is an investigational combination therapy consisting of two antibodies targeting CD20 on B-cells. **DCDS0780A** is an antibody-drug conjugate (ADC) designed to selectively deliver cytotoxic agents to CD20-positive B-cells, leveraging a monoclonal antibody linked to a potent cytotoxin. **Obinutuzumab** is a humanized monoclonal antibody that binds CD20, inducing cell death through direct signaling, complement-dependent cytotoxicity, and antibody-dependent cellular cytotoxicity. This combination aims to enhance antitumor activity by complementary mechanisms of B-cell depletion and targeted cytotoxicity, primarily in B-cell malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. Both drugs have been developed by Roche/Genentech.
- Brand names
- GazyvaGazyvaro
- Other names
- DCDS0780A + obinutuzumab
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainTUBB (Tubulin (alpha and beta subunits))FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on DCDS0780A + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCDS0780A + obinutuzumab.